Prelude Therapeutics Inc (PRLD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Prelude Therapeutics reported revenue of $12.1M, up 73.4% from $7.0M the year before. Net income was -$99.5M (a -819.6% net margin), or -$1.29 per diluted share. Operating margin was -861.3%. Operating activities generated -$56.3M of cash, leaving -$56.4M of free cash flow. At fiscal year end, Prelude Therapeutics held $141.3M in total assets against $72.7M in total liabilities, including $35.3M of cash and equivalents.
Open the full interactive Prelude Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Prelude Therapeutics Key Stats
| Share Price | $3.56 |
|---|---|
| Market Cap | $350.3M |
| Revenue YoY Growth | +73.4% |
| 52-Week Range | $1.19 – $6.63 |
| Shares Outstanding | 98.4 million (basic, 2026 Q2) |
Prelude Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $7.0M | $12.1M |
| Operating Income | -$58.8M | -$113.7M | -$123.5M | -$132.3M | -$139.7M | -$104.6M |
| Pre-Tax Income | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$56.9M | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| Diluted EPS | -$4.56 | -$2.43 | -$2.44 | -$2.02 | -$1.68 | -$1.29 |
Prelude Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $6.5M | $5.6M | $4.6M | $5.7M |
| Net Income | -$19.7M | -$16.5M | -$10.4M | -$13.9M |
| Diluted EPS | -$0.26 | -$0.21 | -$0.13 | -$0.14 |
Prelude Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $218.3M | $31.8M | $30.6M | $25.3M | $12.5M | $35.3M |
| Current Assets | $220.8M | $295.1M | $204.4M | $235.6M | $135.9M | $105.7M |
| Total Assets | $223.6M | $305.1M | $220.5M | $277.7M | $175.5M | $141.3M |
| Current Liabilities | $11.4M | $19.2M | $21.7M | $21.8M | $25.6M | $53.0M |
| Total Liabilities | $11.4M | $19.2M | $25.1M | $40.6M | $44.1M | $72.7M |
| Shareholders' Equity | $212.2M | $285.9M | $195.4M | $237.1M | $131.5M | $68.6M |
Prelude Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$46.2M | -$83.5M | -$83.7M | -$107.1M | -$102.9M | -$56.3M |
| Cash From Investing | -$621,000 | -$263.8M | $81.7M | -$34.6M | $90.2M | $53.5M |
| Cash From Financing | $246.2M | $164.9M | $815,000 | $136.4M | -$120,000 | $24.8M |
| Free Cash Flow | -$46.8M | -$85.9M | -$86.7M | -$110.6M | -$103.7M | -$56.4M |
Figures from Prelude Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Prelude Therapeutics financials page for every line item.
Prelude Therapeutics Company Profile
| Ticker | PRLD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wilmington, Delaware |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001678660 |
Frequently Asked Questions
What was Prelude Therapeutics' revenue in fiscal 2025?
Prelude Therapeutics (PRLD) reported revenue of $12.1M for fiscal 2025.
What is Prelude Therapeutics' annual revenue history?
Prelude Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $7.0M; 2025: $12.1M.
What was Prelude Therapeutics' net income in fiscal 2025?
Prelude Therapeutics reported net income of -$99.5M for fiscal 2025.
What was Prelude Therapeutics' earnings per share (EPS) in fiscal 2025?
Prelude Therapeutics' diluted EPS was -$1.29 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Prelude Therapeutics generate in fiscal 2025?
Prelude Therapeutics generated -$56.4M of free cash flow in fiscal 2025.
What was Prelude Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Prelude Therapeutics reported revenue of $5.7M.
How many shares of Prelude Therapeutics are outstanding?
Prelude Therapeutics reported a weighted average of 98.4 million basic shares outstanding in 2026 Q2.
What is Prelude Therapeutics' market cap?
Based on its latest closing price, Prelude Therapeutics (PRLD) has a market capitalization of about $350.3M.
When does Prelude Therapeutics' fiscal year end?
Prelude Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Prelude Therapeutics headquartered?
Prelude Therapeutics lists its business address in Wilmington, Delaware in its SEC filings.